key: cord-0279427-m7accbl7
authors: Ripoll, Carla Valenzuela; Guo, Zhen; Kumari, Tripti; Miyata, Kana N.; Ozcan, Mualla; Diab, Ahmed; Girardi, Amanda; He, Li; Kovacs, Attila; Weinheimer, Carla; Nigro, Jess; Oscarsson, Jan; Esterline, Russell; Schilling, Joel; Kosiborod, Mikhail; Christoffersen, Christina; Cho, Jaehyung; Javaheri, Ali
title: Dapagliflozin improves endothelial integrity and hemodynamics in endotoxin treated mice through an apolipoprotein M dependent pathway
date: 2022-04-28
journal: bioRxiv
DOI: 10.1101/2022.04.27.489709
sha: 586e3fa41016156c8e9660418328ed933cfd40b2
doc_id: 279427
cord_uid: m7accbl7

Rationale Sodium-glucose co-transporter inhibitors (SGLT2i) are under active clinical investigation in patients with acute inflammatory conditions, based on their clinical cardio-and nephroprotective effects, and a pre-clinical study that demonstrated SGLT2i improve renal outcomes and survival in a lipopolysaccharide (LPS) model. However, a unified mechanism that explains how SGLT2i could prevent hemodynamic consequences of inflammatory conditions has not been described. Apolipoprotein M (ApoM) is inversely associated with mortality in inflammatory conditions and improves cardiac function in endotoxin-treated mice via sphingosine-1-phosphate (S1P) signaling. Objective Test the hypothesis that pre-treatment with SGLT2i dapagliflozin (Dapa) improves hemodynamics in endotoxin-treated mice via the ApoM/S1P pathway. Methods and Results Mice with diet-induced obesity were gavaged with vehicle or Dapa for 4 days prior to LPS (10 mg/kg, IP). We found that mice receiving Dapa restored circulating ApoM levels, likely by increasing expression of the multi-ligand protein receptor megalin in the proximal tubules. Dapa attenuated LPS-induced reductions in cardiac dysfunction including reductions in ejection fraction, cardiac index, and coronary sinus area as well as vascular permeability as ascertained by intravital microscopy. Using both ApoM transgenic and knockout mice and S1P receptor inhibitors, we show that the ApoM/S1P pathway is important for the beneficial effects of Dapa in the LPS model. Conclusions In the setting of acute inflammation, our data suggest that SGLT2i maintains levels of megalin, leading to preservation of ApoM, which in turn promotes endothelial barrier integrity and improves hemodynamics. Our studies suggest a novel mechanism by which SGLT2i can preserve intravascular volume in the acute inflammatory setting.

Sodium-glucose co-transporter inhibitors (SGLT2i) such as dapagliflozin (Dapa) have 50 well-described clinical benefits in diabetes, heart failure (HF) and chronic kidney disease (1-5). 51

Interestingly, a recent post-hoc analysis of the Dapagliflozin in Patients with Chronic Kidney 52

Disease trial demonstrated reduced infectious death in patients treated with SGLT2i (6), findings 53 that are concordant with preclinical studies suggesting that SGLT2i can improve survival and 54

Ly6G-Cre LoxP-STOP-TdTomato mice on chow diet were treated with vehicle or 149 VPC23019 (0.75 mg/kg body weight (BW) IP daily) and gavaged with vehicle or dapagliflozin 150

(1.25 mg/kg) for 4 days before IP injection of LPS (7.5 mg/kg). Twenty-four hours after LPS 151 challenge, intravital microscopy was performed as we described (27) . FITC-conjugated dextran 152

(1 mg/g) was infused into a jugular venous cannulus. Neutrophil recruitment and vascular leak 153

were monitored in an area of 0.02 mm 2 (number/field/5 minutes) in the inflamed cremaster 154 venules with a diameter of 25-40 μm. The number of neutrophils that visibly roll over the 155 inflamed endothelium over 5 minutes were counted by an observer blinded to the treatment 156 groups and unfamiliar with the study hypotheses. Adherent neutrophils were defined as 157 neutrophils that were stationary for more than 30 seconds or crawled on the inflamed 158 endothelium but did not roll over. respectively. Fluorescence and bright-field images were recorded using a Zeiss Axio examiner 167 Z1 microscope system with a Yokogawa confocal spinning disk (CSU-W1) equipped with four 168 stack laser system (405 nm, 488 nm, 561 nm, and 637 nm wave lengths). Images were 169 collected with a high-speed, high-resolution camera (2304 x 2304 pixel format, ORCA-Fusion 170 BT sCMOS, Hamamatsu). Data were analyzed using SlideBook, version 6.0 (Intelligent Imaging 8 Innovations). Each curve is the median extravascular FITC-Dextran intensity across the 172 quantified vessels (n = 5 vessels per mouse, 3-5 mice per group). 173

Sample size was estimated based on literature review of murine SGLT2i studies (7, 28). 175

Data were considered non-normally distributed if either the Shapiro-Wilk or Kolmogorov-176

Smirnov tests were statistically significant (P < 0.05). Data are presented as mean ± SEM or 177 median ± 95% CI and analyzed by GraphPad Prism 9.0. Statistical significance among multiple 178 groups was analyzed by analysis of variance (ANOVA) and multiple testing corrections as 179 specified in each figure legend. In all of the analyses, a value of P < 0.05 was considered 180 statistically significant. 181

All murine studies were approved by the Institutional Animal Care and Usage Committee To test our hypothesis that Dapa preserves circulating ApoM in acute inflammation, we 191 utilized a model of diet-induced obesity (DIO) generated by feeding mice 60% high-fat high-192 calorie diet from 6 to 16 weeks of age. We performed studies in DIO mice, because it is a well-193 described model of pre-diabetes, obesity, and impaired glucose tolerance (29, 30), pathologies 194 known to reduce ApoM (31, 32). DIO mice underwent oral gavage with vehicle or Dapa (1.25 9 mg/kg daily), prior to saline or LPS injection (10 mg/kg IP) on Day 4, followed by in vivo 196 phenotyping (see below) and euthanasia on Day 5. LPS administration induced hypothermia, 197 weight loss, and transient hypoglycemia, none of which was influenced by Dapa 198 (Supplementary Figure 1) . 199

In DIO mice, Dapa pre-treatment significantly attenuated LPS-induced decreases in 200 circulating ApoM (Figure 1A, B) . In contrast, Dapa did not have a significant effect on serum 201 albumin concentrations ( Figure 1C) . We thus investigated how Dapa might attenuate LPS-202

induced reductions in ApoM. The liver, and to a lesser extent the kidney, are the main sites of 203

ApoM production (18). We found that while LPS reduces both hepatic ApoM protein abundance 204 and renal ApoM protein and mRNA abundance, none of these were affected by Dapa ( Figure  205 1D-I). Since we did not find considerable change in ApoM mRNA and protein abundance in 206 either the liver or the kidney, we sought to examine other potential mechanisms by which Dapa 207 might preserve circulating ApoM. 208

Hepatic ApoM clearance is dependent on low-density lipoprotein receptor (LDLR) uptake 209 (33); however, LPS suppressed LDLR equally in both vehicle and Dapa-treated mice ( Figure  210 2A, B), suggesting that hepatic ApoM clearance was unlikely to be responsible for the observed 211 increase in circulating ApoM. Alternatively, we hypothesized that Dapa regulates ApoM 212 reabsorption, which occurs in the renal proximal tubule by the protein receptor megalin (Lrp2) 213 S1P signaling, we tested the combined effect of Dapa and S1PRi. We found that compared with 253 vehicle, S1PRi significantly increased vascular leak, and that treatment with S1PRi blocked the 254 effect of Dapa on FITC-Dextran extravasation ( Figure 4A, B and Supplementary Figure 3) . 255

Pre-treatment with Dapa increased the number of rolling neutrophils, and decreased the number 256 of adherent neutrophils (Figure 4C, D) ; nonetheless, S1PRi blocked the effects of Dapa on 257 rolling neutrophils, but not adherent neutrophils, implying that Dapa in part affects neutrophil 258 recruitment in a S1PR-dependent manner. Importantly, we did not observe any consistent 259 effects of Dapa on S1P receptor expression (Supplementary Figure 4) , or significant increases 260 in the number of circulating neutrophils (Supplementary Figure 5) . These results indicate that 261

Dapa prevents vascular leak induced by LPS, an effect dependent on S1PR signaling. 262

Given that Dapa prevented reductions in circulating ApoM in LPS-treated DIO mice, we 263 sought to determine whether ApoM mediated the effects of Dapa on endothelial integrity and 264 neutrophils. To test this, we utilized both ApoM knockout mice (Apom KO ), which exhibit 50% 265 reductions in plasma S1P (9), and mice with hepatocyte-specific overexpression of human 266 APOM (Apom TG ), which results in 3-5 fold increase in plasma ApoM and S1P (14). While 267 Apom KO mice exhibited increased vascular leak compared to littermate controls following LPS, 268

Dapa did not significantly reduce FITC-Dextran extravasation in Apom KO mice (Figure 4E and 12 rolling and adhesion on the inflamed endothelium. Dapa pretreatment did not affect neutrophil 271 rolling and adhesion in Apom KO mice (Figure 4F, G) . In contrast, IVM demonstrated that 272

Apom TG mice exhibit reduced vascular leak (Figure 4H and Supplementary Figure 7) , fewer 273 rolling neutrophils (Figure 4I) , and more adherent neutrophils (Figure 4J ), but Dapa 274 pretreatment did not significantly alter any of these parameters in Apom TG mice. These results 275

suggest that Dapa reduces LPS-induced endothelial leak via Apom-S1P signaling, but that the 276 effect of Dapa on neutrophil recruitment may only be partially dependent on ApoM/S1P. where ApoM is also inversely associated with clinical severity (20, 21). 296

One of the main findings of our study is that SGLT2i preserved cardiac preload, as 297 evidenced by preserved end-diastolic volume index, coronary sinus area, and an increased right ApoM mRNA abundance in (I) (n = 3-7). All data are presented as mean ± SEM. *P < 0.05, **P 504 < 0.01, ***P < 0.001, ****P < 0.0001. Each dot represents one mouse. One-way ANOVA with prior to LPS (10 mg/kg IP). A) Representative Western blot for LDL receptor and quantification 511 in (B) (n = 4). C) Immunofluorescence staining for megalin/Lrp2 (Green) and DAPI in kidney 512 frozen sections with quantification of mean fluorescence intensity in (D) (n = 5-11). Scale bar = 513 50 μm. E) Representative fluorescence images were obtained from HK2 cells which were grown 514 on 8-chamber slides for 24 hours, thereafter, exposed to Dapaliflozin (6 nM) or vehicle for 16 515 hours, followed by addition of LPS (0.1 µg/ml) or saline as well as ApoM-GFP (2100 arb units) 516

for further 6 hours. Scale bar = 20 μm. F) Quantification of mean fluorescence intensity in (E) (n 517 = 6-8). All data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < treated with the S1P receptor 1 and 3 inhibitor (S1PRi, 0.75 mg/kg IP daily), simultaneously 531 gavaged with dapagliflozin or vehicle for 4 days before saline or LPS (10 mg/kg IP) followed the 532 next day by echocardiography and quantitative assessment of ejection fraction, cardiac index, 533 and coronary sinus area, respectively (n = 4-6). All data are presented as mean ± SEM or 534 median ± 95% CI. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Each dot represents one 535 mouse. One-way ANOVA with Sidak's correction for multiple comparisons in panels (B-E) and 536 for assessment of extravascular FITC-Dextran and rolling and adherent neutrophils. All 553 experiments quantified vessels (> 4 per mouse, n = 3-5 mice per group. Each dot represents 554 one vessel. All data are presented as mean ± SEM or median ± 95% CI. *P < 0.05, **P < 0.01, 555 ***P < 0.001, ****P < 0.0001. One way ANOVA with Sidak's correction for multiple comparisons 556 

Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection 364 Fraction: A Prespecified Analysis of DAPA-HF

Efficacy 366 of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced 367 Ejection Fraction: Results of DAPA-HF

Dapagliflozin in Patients with Chronic Kidney Disease

Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and

Reduced Ejection Fraction: Results From the DAPA-HF Trial

Clinical Benefit of Cardiorenal Effects of Sodium-Glucose 374

Cotransporter 2 Inhibitors: JACC State-of-the-Art Review

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified 377 analysis from the DAPA-CKD randomized controlled trial

Empagliflozin suppresses 379 inflammation and protects against acute septic renal injury

Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on 383 sphingosine-1-phosphate receptor 1

Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein

Sphingosine 1-388 phosphate and its carrier apolipoprotein M in human sepsis and in Escherichia coli sepsis in 389 baboons

Phosphate to the Sphingosine-1-Phosphate Receptor 1

Apolipoprotein M: progress in understanding 395 its regulation and metabolic functions

A novel human apolipoprotein (apoM)

Hepatic apolipoprotein M 399 (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched 400 plasma high density lipoprotein

Isolation 402 and characterization of human apolipoprotein M-containing lipoproteins

HDL composition, heart failure, and its 405 comorbidities

Decreased plasma concentrations 407 of apolipoprotein M in sepsis and systemic inflammatory response syndromes

Infection 410 and inflammation decrease apolipoprotein M expression

Apolipoprotein M Protects Lipopolysaccharide-Treated Mice from Death and Organ Injury

Proteomic and Metabolomic 415 Characterization of COVID-19

Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in 418 COVID-19

Reduced Apolipoprotein M 420 and Adverse Outcomes Across the Spectrum of Human Heart Failure

Plasma apoM and 423 S1P levels are inversely associated with mortality in African Americans with type 2 diabetes 424 mellitus

Catchup: a mouse model for imaging-based tracking and modulation of neutrophil granulocytes

Ma X, Mani K, Liu